

Vito Di Marco

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/668524/vito-di-marco-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

165
papers

6,527
citations

47
h-index

75
g-index

170
ext. papers

7,709
ext. citations

5.6
avg, IF

5.12
L-index

#	Paper	IF	Citations
165	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
164	Random Forest Clustering Identifies Three Subgroups of β -Thalassemia with Distinct Clinical Severity. <i>Thalassemia Reports</i> , 2022 , 12, 14-23	2	1
163	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022 , 12, 1187	3.8	
162	Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence. <i>Annals of Hepatology</i> , 2021 , 100568	3.1	1
161	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021 , 53, 1301-1307	3.3	2
160	Survival and causes of death in 2,033 patients with non-transfusion-dependent β -thalassemia. <i>Haematologica</i> , 2021 , 106, 2489-2492	6.6	3
159	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1190-1199	3.4	3
158	Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021 , 67, 254-263	3	1
157	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , 2021 , 74, 1496-1508	11.2	4
156	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021 , 41, 2179-2188	7.9	1
155	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2389-2396	4	3
154	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2345-2353	4.5	17
153	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021 , 40, 407-416	4.3	5
152	A complication risk score to evaluate clinical severity of thalassaemia syndromes. <i>British Journal of Haematology</i> , 2021 , 192, 626-633	4.5	2
151	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021 , 74, 340-349	13.4	11
150	Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1248-1255	0.7	2
149	Perception of the Role of Food and Dietary Modifications in Patients with Inflammatory Bowel Disease: Impact on Lifestyle. <i>Nutrients</i> , 2021 , 13,	6.7	3

148	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
147	Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy. <i>Journal of Hospital Infection</i> , 2021 , 115, 51-58	6.9	0
146	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1979-1981	6.9	4
145	Risk of mortality from anemia and iron overload in nontransfusion-dependent β -thalassemia. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
144	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020 , 296, 40-47	3.1	36
143	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020 , 40, 530-538	7.9	1
142	Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020 , 30, 1048-1053	3.1	2
141	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020 , 40, 2820-2827	7.9	9
140	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2408-2416	6.7	28
139	Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3477-3480	4	1
138	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 935-944.e3	6.9	55
137	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study). <i>Liver International</i> , 2019 , 39, 2240-2243	7.9	3
136	Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019 , 51, 915-921	3.3	8
135	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019 , 71, 265-273	13.4	80
134	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019 , 8,	7.9	9
133	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-128	5.38	5
132	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 310-317	3.3	29
131	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019 , 47, 409-415	5.8	3

130	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018 , 69, 18-24	13.4	68
129	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018 , 38, 2060-2068	7.9	39
128	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018 , 155, 411-421.e4	13.3	201
127	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1705-1712 ²¹	6.1	21
126	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 878-885	13.4	75
125	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018 , 391, 2417-2429	4.0	176
124	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. <i>Hepatology</i> , 2017 , 66, 736-745	11.2	53
123	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017 , 37, 1526-1534	7.9	29
122	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
121	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
120	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017 , 92, 1349-1355	7.1	33
119	Interferon lambda 4 rs368234815 TT>C variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017 , 66, 1885-1893	11.2	59
118	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
117	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 688-695	6.1	104
116	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017 , 65, 1145-1155	11.2	135
115	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 312-21	7	28
114	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 682-90	13.4	79
113	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , 2016 , 48, 650-5	3.3	6

112	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016 , 36, 198-204	7.9	12
111	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , 2016 , 151, 130-139.e2	13.3	107
110	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015 , 61, 506-14	11.2	311
109	Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 477-86	6.1	12
108	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 939-48	6.1	16
107	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 928-33	13.4	115
106	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015 , 35, 1566-73	7.9	94
105	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015 , 9, 52-7	8.8	7
104	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015 , 62, 1101-10	11.2	131
103	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015 , 2015, 431750	3.4	13
102	Impact of HBV genotypes A and D genetic variability on infection evolution. <i>Infection, Genetics and Evolution</i> , 2015 , 33, 281-7	4.5	4
101	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015 , 82, 48-52	3.6	8
100	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 818-25	3.3	8
99	HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2014 , 23, 80-5	4.5	2
98	Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 878-884.e1	6.9	10
97	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 523-9	13.4	57
96	Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014 , 60, 16-21	13.4	23
95	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83

94	Targeted therapies in hepatocellular carcinoma. <i>Current Medicinal Chemistry</i> , 2014 , 21, 966-74	4.3	17
93	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013 , 59, 1169-76	13.4	28
92	Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 867-74	3.4	67
91	Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 113-21	3.4	16
90	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 174-82	3.4	10
89	Randomised study comparing 48 and 96 weeks peginterferon α 2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013 , 62, 290-8	19.2	88
88	Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. <i>Hepatitis Monthly</i> , 2013 , 13, e7176	1.8	10
87	Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 790-800	3.4	10
86	Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. <i>PLoS ONE</i> , 2013 , 8, e70016	3.7	20
85	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2013 , 8, e74089	3.7	47
84	Methylenetetrahydrofolate reductase homozygosity and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 465-72	3.4	8
83	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , 2012 , 97, 679-86	6.6	41
82	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. <i>Journal of Hepatology</i> , 2012 , 56, 1254-8	13.4	29
81	Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , 2012 , 23, e124-7	3.9	12
80	Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy. <i>Infection, Genetics and Evolution</i> , 2012 , 12, 1591-6	4.5	6
79	Serum γ -glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. <i>PLoS ONE</i> , 2012 , 7, e51165	3.7	24
78	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. <i>Hepatology</i> , 2012 , 55, 1317-23	11.2	105
77	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 850-60	11.2	91

76	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 92-104	6.1	36
75	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 238-47	6.1	74
74	Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up. <i>Journal of Computer Assisted Tomography</i> , 2012 , 36, 20-5	2.2	29
73	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , 2012 , 17, 823-31	1.6	28
72	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2012 , 4, 256-61	3.4	59
71	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011 , 43, 259-65	3.3	25
70	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011 , 43, 404-10	3.3	24
69	Chronic hepatitis C in children is a mild and curable liver disease. <i>Digestive and Liver Disease</i> , 2011 , 43, 266-7	3.3	4
68	Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011 , 43, 875-80	3.3	21
67	Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. <i>Digestive and Liver Disease</i> , 2011 , 43, 996-1000	3.3	10
66	Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2011 , 106, 2112-20	0.7	148
65	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 1350-60	6.1	104
64	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 196-204	6.1	46
63	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 757-66	6.1	95
62	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1202-16	6.1	94
61	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e372-80	3.4	17
60	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , 2011 , 60, 1023	19.2	9
59	Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. <i>British Journal of Haematology</i> , 2010 , 148, 476-9	4.5	45

58	Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. <i>Digestive and Liver Disease</i> , 2010 , 42, 585-92	3.3	24
57	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010 , 116, 2875-83	2.2	65
56	Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 469-74	3.4	23
55	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010 , 52, 1543-52	11.2	76
54	Hepatitis B: Prognosis and Treatment 2010 , 448-464		
53	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2132-8	5.6	27
52	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009 , 49, 195-203	11.2	56
51	SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009 , 49, 1821-7	11.2	132
50	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 603-13	6.1	20
49	Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. <i>Liver International</i> , 2009 , 29, 1171-7	7.9	19
48	Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009 , 7, 281-91	5.5	7
47	Chronic hepatitis B: Do we know everything or is there still something to learn?. <i>Digestive and Liver Disease Supplements</i> , 2009 , 3, 61-66		
46	Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. <i>Journal of Oral Pathology and Medicine</i> , 2009 , 38, 34-41	3.3	4
45	Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2009 , 14, 649-654	1.6	39
44	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 523-30	3.4	15
43	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. <i>Digestive and Liver Disease</i> , 2008 , 40, 684-9	3.3	25
42	Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. <i>Haematologica</i> , 2008 , 93, 1243-6	6.6	41
41	Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 66-70	3.4	3

40	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008 , 48, 28-37	11.2	49
39	HCV clearance among hemophiliacs and beta-thalasseemics. <i>Gastroenterology</i> , 2007 , 132, 1634	13.3	5
38	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007 , 39, 397-408	3.3	172
37	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1181-91	6.1	59
36	Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an in vitro culture system. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 1471-7	6.1	11
35	Oral pathology in untreated coeliac [corrected] disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1529-36	6.1	33
34	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. <i>Journal of Hepatology</i> , 2007 , 47, 484-91	13.4	84
33	Adefovir for lamivudine resistant HBV: more than meets the eye. <i>Journal of Hepatology</i> , 2007 , 47, 618-9; author reply 619-20	13.4	2
32	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 64-71	11.2	147
31	Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1154-9	11.6	92
30	Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. <i>Kidney International</i> , 2006 , 70, 1187-8	9.9	8
29	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005 , 42, 535-40	13.4	89
28	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <i>Digestive and Liver Disease</i> , 2005 , 37, 882-5	3.3	19
27	Congenital hepatic fibrosis: a very uncommon cause of pancytopenia in children. <i>Journal of Pediatric Hematology/Oncology</i> , 2005 , 27, 567-8	1.2	5
26	Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2472-7	0.7	48
25	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004 , 40, 478-83	13.4	35
24	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <i>Journal of Hepatology</i> , 2004 , 40, 831-6	13.4	38
23	Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004 , 41, 474-81	13.4	83

22	Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004 , 40, 883-91	11.2	199
21	Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. <i>Journal of Medical Virology</i> , 2003 , 70, 581-7	19.7	29
20	A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , 2003 , 35, 372-3	3.3	0
19	Parvovirus B19 and "cryptogenic" chronic hepatitis. <i>Journal of Hepatology</i> , 2003 , 38, 375-6	13.4	13
18	Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <i>Journal of Viral Hepatitis</i> , 2002 , 9, 354-9	3.4	12
17	Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002 , 51, 864-9	19.2	19
16	Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. <i>Digestive and Liver Disease</i> , 2002 , 34, 53-8	3.3	5
15	High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 953-8	6.1	5
14	Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. <i>Journal of Hepatology</i> , 2000 , 33, 456-62	13.4	40
13	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1013-9	4	11
12	The long-term course of chronic hepatitis B. <i>Hepatology</i> , 1999 , 30, 257-64	11.2	170
11	Long-term course of interferon-treated chronic hepatitis C. <i>Journal of Hepatology</i> , 1998 , 28, 531-7	13.4	71
10	A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , 1997 , 51, 17-24	19.7	19
9	Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months. <i>Journal of Hepatology</i> , 1996 , 24, 539-46	13.4	20
8	HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). <i>Journal of Hepatology</i> , 1996 , 25, 583-90	13.4	32
7	Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. <i>Hepatology</i> , 1994 , 19, 820-8	11.2	91
6	Long-term evolution of chronic delta hepatitis in children. <i>Journal of Pediatrics</i> , 1993 , 122, 736-8	3.6	13
5	Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia. <i>Gut</i> , 1993 , 34, S142-3	19.2	13

- 4 Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. *Journal of Hepatology*, **1991**, 12, 64-9 13.4 25
- 3 Hepatitis C virus replication in chronic liver disease. *Journal of Hepatology*, **1991**, 13 Suppl 4, S40-1 13.4
- 2 Treatment with interferon alfa-2b of chronic HDV hepatitis in children. *Journal of Hepatology*, **1990**, 11, S175 13.4 6
- 1 Detection of hepatitis delta virus RNA in chronic liver disease. *Journal of Hepatology*, **1989**, 9, 23-8 13.4 15